A US lawmaker has introduced a bill to improve the Food and Drug Administration’s (FDA) accelerated approval program.
Energy and Commerce Committee Chairman Frank Pallone Junior’s proposed Accelerated Approval Integrity Act would enhance the FDA’s ability to ensure that drugs that receive accelerated approval are providing a proven clinical benefit to patients.
"Patients deserve to know that the drugs they are taking are safe and effective"He said: “The Accelerated Approval Program allows patients to access innovative new drugs while the manufacturer and FDA conduct additional studies to confirm the product’s clinical benefit.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze